Why Ono’s Phase 2 MSA data may matter beyond one World Parkinson Congress poster
Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.
Pharma & Biotech
Pharma & Biotech
Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Pharma & Biotech
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.
Pharma & Biotech
Can AviadoBio’s thalamic delivery strategy give AVB-101 an edge in frontotemporal dementia?
AviadoBio’s AVB-101 has moved into a new ASPIRE-FTD cohort. Read what the early biomarker, safety, and strategy signals could mean next.
Pharma & Biotech
Can Lunai Bioworks Inc.’s BBB delivery platform unlock scalable Alzheimer’s drug development advantages?
Can Lunai Bioworks Inc. overcome the blood brain barrier in Alzheimer’s treatment? Discover what this $20M deal changes for CNS drug development.
Pharma & Biotech
What Celosia Therapeutics’ Phase 1b CTx1000 trial could reveal about TDP-43 targeting in ALS
Celosia Therapeutics has dosed the first ALS patient with CTx1000. Read why this TDP-43 gene therapy trial could reshape the ALS pipeline.
Pharma & Biotech
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Pharma & Biotech
IntraBio leverages prior Niemann-Pick approval to seek FDA expansion of levacetylleucine into Ataxia-Telangiectasia
IntraBio files the first-ever FDA application for an A-T therapy. Analyse the Phase III evidence, regulatory pathway, and what approval would mean.
Pharma & Biotech
Cognition Therapeutics advances regulatory strategy for zervimesine in an underserved neurodegenerative disease
Cognition Therapeutics aligns with FDA on zervimesine Phase 2b plans. Discover what this means for dementia with Lewy bodies drug development.
Pharma & Biotech
FDA priority review for Leqembi Iqlik could transform Alzheimer’s drug initiation at home
Leqembi Iqlik gets FDA Priority Review for at-home Alzheimer’s treatment initiation. Find out what this could mean for patients, payers, and the care model.